
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+21
TwinStrand Biosciences Duplex Sequencing patent estate is the foundational technology enabling the ability to accurately identify ultra-low frequency genomic variants that are undetectable by conventional NGS methods. The companys highly sensitive and specific patented Duplex Sequencing technology delivers clearer insights to researchers in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in public health, and other fields of science on a faster timescale when actions are most impactful. TwinStrands scientist-leaders have authored more than thirty peer-reviewed articles using Duplex Sequencing technology and have developed a portfolio of more than 150 patents and patent...
Duplex sequencing,ultra-rare variant detection,genetic toxicity,carcinogenesis,mutagenesis,tumor evolution,error corrected sequencing,direct mutation detection,cloud-based bioinformatics,eliminating ngs noise,sequencing mutation discovery,dna mixture deconvolution,microhaplotypes,liquid biopsy,residual disease monitoring,minimum residual disease detection,ffpe,next-generation sequencing,eliminating ngs background errors,targeted biomarker validation,mutation signature discovery,crispr validation,drug candidate selection,targeted dna sequencing,profiling environmental exposure,and early cancer detection
Twinstrand biosciences operates in the Biotechnology research industry.
Twinstrand biosciences's revenue is 11m - 100m
Twinstrand biosciences has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.